BCWorld Pharm Expands Antibiotic Exports, Eyes Pediatric Drug Launch

BCWorld Pharm is expanding its carbapenem antibiotic business beyond South Korea, with overseas sales increasingly centered on Southeast Asia. Industry observers say that if this momentum continues—and if the company’s pediatric severe drooling treatment achieves a smooth market entry—the group could secure a new driver of sustainable growth.

At a New Year’s ceremony, founder and CEO Seong-han Hong said, “In 2026, we aim to successfully launch our pediatric severe drooling treatment and establish a solid foundation for the global expansion of our carbapenem antibiotics.”

The company’s antibiotic business has shown steady growth. According to disclosures released on January 28, 2024, BCWorld Pharm posted total revenue of $52.4 million, with antibiotics contributing $19.3 million, or 36.9% of the total. Antibiotic sales rose 5.2% from $18.3 million in 2022 to $19.3 million in 2024, while third-quarter 2025 revenue reached $14.2 million, up 6.3% year on year.

Industry sources attribute this performance to BCWorld Healthcare, a subsidiary that operates a dedicated carbapenem production facility designed to fundamentally eliminate cross-contamination risks. A production executive at a mid-sized pharmaceutical company noted, “BCWorld Pharm places strong emphasis on sterile management. The decision to invest aggressively in a separate antibiotic facility is now translating into tangible results.”

After the Ministry of Food and Drug Safety (MFDS) mandated the physical separation of antibiotic manufacturing from other production lines in 2018, most companies opted to renovate existing facilities. BCWorld Pharm instead built a new antibiotic plant in Wonju, Gangwon Province, investing approximately $21.7 million.

To further enhance quality, the Wonju plant operates a “One Line” production system, in which processes run continuously from start to finish. This approach minimizes waiting time and unnecessary movement, improving both production efficiency and stability for sterile products.

A production head at a major pharmaceutical company said, “The One Line system simplifies quality control and reduces risks such as human error or contamination. This has strengthened trust in the quality of BCWorld’s carbapenem antibiotics and helped drive demand, particularly in Southeast Asian markets with relatively weaker medical infrastructure.”

Exports of carbapenem antibiotics produced at the Wonju plant—most notably meropenem—have expanded accordingly. Shipments initially began to Southeast Asian markets such as the Philippines and Vietnam, and later extended to Mongolia, Myanmar, Thailand, and Cambodia. More recently, BCWorld Pharm signed an export contract with Iraq, and last April drew attention after the Wonju plant completed manufacturing site registration with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). Company data show carbapenem exports totaled $3.5 million last year.

Beyond antibiotics, BCWorld Pharm is preparing to launch its pediatric severe drooling treatment, Sialanar, next month. Sialanar is a peripherally acting anticholinergic indicated for children with chronic neurological disorders and severe drooling. It has attracted attention as there is currently no approved drug in Korea specifically indicated for chronic severe drooling.

A development executive at a major pharmaceutical company commented, “Sialanar represents a strategic opportunity to open an entirely new market. In Korea, pediatric severe drooling has largely been managed with limited off-label use of injections or oral drugs, with insufficient data on long-term safety and efficacy.”

While drooling is considered normal in children under four, persistent symptoms beyond that age are often associated with conditions such as cerebral palsy or impaired oral muscle development. In Korea, anticholinergic drugs or toxin injections have been used on a short-term basis, but standardized dosing guidelines and long-term safety data remain limited. By contrast, Sialanar is approved by the European Medicines Agency (EMA) and is widely used overseas as a first-line therapy.

Industry observers say that a successful launch of Sialanar, combined with continued growth in global antibiotic exports, could provide BCWorld Group with renewed momentum. One industry source noted, “The group’s revenue growth has recently plateaued around the $49 million level. If Sialanar enters the market smoothly and antibiotic exports continue to accelerate, BCWorld could return to a clear upward growth trajectory.”